NAD+ vs MOTS-c vs SS-31 — Mitochondrial Research Compounds
QSC Research Guide
NAD+ vs MOTS-c vs SS-31 — Mitochondrial Research Compounds
Three compounds targeting mitochondrial function via distinct mechanisms — NAD+ (coenzyme), MOTS-c (mtDNA-encoded peptide), and SS-31 (cardiolipin stabiliser). Each addresses different aspects of mitochondrial biology and aging.
Side-by-Side Comparison
Attribute
NAD+
MOTS-c
SS-31 (Elamipretide)
Mechanism class
Mitochondrial coenzyme
Mitochondria-derived peptide (mtDNA)
Cardiolipin-targeting tetrapeptide
Receptor targets
Sirtuin (SIRT1-3), PARP1-2, CD38
AMPK (via AICAR-like mechanism)
Inner mitochondrial membrane cardiolipin
Half-life
Short (precursor NMN/NR preferred for oral)
~30 min
~2 hours
Key advantage
Central redox coenzyme for sirtuins and PARP — broad pathway coverage. Injectable NAD+ bypasses precursor conversion
mtDNA-encoded — first characterised mitochondria-nuclear retrograde signalling peptide; AMPK activation as exercise mimetic
Directly targets inner mitochondrial membrane — stabilises cristae, restores respiratory chain efficiency. Clinical data in heart failure
Best for research
Sirtuin pathway, DNA repair (PARP), NAD+ depletion models
These three compounds address different mitochondrial layers: NAD+ is the central redox currency for sirtuin and PARP pathways; MOTS-c is an AMPK-activating retrograde signal from mtDNA; SS-31 physically stabilises the inner mitochondrial membrane at the cardiolipin level. They are mechanistically complementary and often studied in combination in comprehensive longevity protocols.
Frequently Asked Questions
What is the difference between NAD+, MOTS-c, and SS-31?
NAD+ is the central metabolic coenzyme activating sirtuins and PARP. MOTS-c is a peptide encoded in mitochondrial DNA that activates AMPK as an exercise mimetic. SS-31 is a small peptide that directly binds cardiolipin to stabilise the inner mitochondrial membrane and restore respiratory chain efficiency. They target different mitochondrial functions.
Can NAD+, MOTS-c, and SS-31 be studied together?
Yes. These three compounds target different mitochondrial pathways and are not redundant. NAD+ feeds sirtuin/PARP biology; MOTS-c activates AMPK metabolic reprogramming; SS-31 stabilises the physical mitochondrial membrane. All three are included in multi-compound longevity research protocols for comprehensive mitochondrial coverage.
Which has the most clinical data — NAD+, MOTS-c, or SS-31?
SS-31 (Elamipretide) has the most formal clinical trial data — Phase 2/3 trials in heart failure (STARGAZE) and renal disease. NAD+ precursors (NMN, NR) have multiple human trials. MOTS-c is primarily preclinical with early human data. For clinical reference, SS-31 has the strongest dataset.
Research Use Only: All QSC compounds are sold strictly for laboratory research purposes only. Not for human consumption, veterinary use, or any other application. Researchers are responsible for compliance with local regulations.
QSC Network
Compound reference, COA verification, and regional warehouse information across the QSC network.
